Obesity: an innately incurable disease?
Obese patients need the food-intake reducing operations maintained lifelong; the real cause of obesity is not curable until now, and only the main symptom, "overweight," can be improved by therapy.
Golimumab (50 mg or 100 mg) maintained clinical response through week 54 in patients who responded to induction therapy with golimumab and had moderate-to-severe active ulcerative colitis; patients who received 100 mg golimumab had clinical remission and mucosal healing at weeks 30 and 54. Safety was consistent with that reported for other TNFα antagonists and golimumab in other approved indications. ClinicalTrials.gov number: NCT00488631.